Childhood/AYA Cancer

FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease

August 26, 2022

Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.

Collaboration Between Pediatric Oncology Nurses and Social Workers Decreases Treatment-Related Distress

July 20, 2022

Pediatric oncology nurses and social workers routinely collaborate not only in the biopsychosocial assessment of families’ psychosocial needs and distress, but in developing interventions that can improve a patient’s and family’s quality of life while in pediatric cancer treatment and in survivorship.